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Summary 
Opportunistic infections, such as aspergillosis,  are among the most serious complications suf- 
fered by immunocompromised patients. Aspergillus fumigatus and other pathogenic fungi syn- 
thesize a toxic epipolythiodioxopiperazine metabolite called gliotoxin. Gliotoxin exhibits pro- 
found immunosuppressive activity in vivo. It induces apoptosis in thymocytes, splenocytes, and 
mesenteric lymph node cells and can selectively deplete bone marrow of mature lymphocytes. 
The molecular mechanism by which gliotoxin exerts these effects remains unknown. Here, we 
report that nanomolar concentrations of gliotoxin inhibited the activation of transcription fac- 
tor NF-~B in response to a variety of stimuli in T and B cells. The effect ofgliotoxin was spe- 
cific because, at the same concentrations, the toxin did not affect activation of the transcription 
factor NF-AT  or of interferon-responsive signal  transducers  and  activators of transcription. 
Likewise, the activity of the constitutively DNA-binding transcription factors Oct-1 and cyclic 
AMP response element binding protein (CREB), as well as the activation of protein tyrosine 
kinases p56  lck and p59  fyn, was  not altered by gliotoxin. Very high concentrations of gliotoxin 
prevented NF-~B DNA binding in vitro. However, in intact cells, inhibition of NF-~13  did 
not occur at the level of DNA binding; rather, the toxin appeared to prevent degradation of 
IKB-ci, NF-KB's inhibitory subunit. Our data raise the possibility that the immunosuppression 
observed during aspergillosis  results in part from gliotoxin-mediated NF-KB inhibition. 
B 
ecause  of the  development of intensive combination 
chemotherapy and  bone  marrow  transplant  prepara- 
tory regimens, both of which cause prolonged myelosup- 
pression,  the  incidence of fungal infections in  cancer pa- 
tients  has  risen  sharply  in  the  past  decades  (1).  Fungal 
infections are now the  cause of death in  40% of patients 
with acute leukemia at some hospitals. In a recent interna- 
tional survey (2), 30% of  mycotic infections represented cases 
ofaspergillosis, which is caused by the fungi Aspergillusfumi- 
gatus, A. flavus, A.  niger, and A.  terreus. Aspergillosis  carries 
a very high mortality rate, survival ranging only between 5 
and 20%. 
The precise molecular mechanism of Aspergillus  patho- 
genesis remains  unclear.  One possible  etiological agent is 
the secondary fungal metabolite gliotoxin. This metabolite 
is produced in large quantifies by fungal cultures and can be 
isolated from mice  undergoing systemic experimental as- 
pergillosis  (3).  Gliotoxin belongs  to  the  epipolythiodiox- 
opiperazine class of compounds  and is lethal at relatively 
low  concentrations (LDs0 in mice and rats:  25-50 mg/kg) 
(4). Gliotoxin exhibits profound immunosuppressive effects 
in  vivo.  Sublethally  irradiated  mice  injected  intraperito- 
neally with gliotoxin showed a significant delay in the re- 
covery of  immune cells compared with untreated irradiated 
controls (5). Whereas LPS-responsive B cells were detected 
by proliferation assays in control animals  14 d after irradia- 
tion, animals treated with a single dose of 100 Ftg gliotoxin 
showed no measurable B cell response until 30 d after irra- 
diation. By contrast, the recovery of the T  cell response, as 
measured by Con A-stimulated cell proliferation, was equal 
in both mock- and gliotoxin-treated animals.  The in vivo 
data  differ somewhat  from  observations  in  vitro,  where 
gliotoxin inhibits mitogen-induced proliferation of both B 
and T cells. Furthermore, in MLCs, pretreatment ofstimu- 
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tion of alloreactive cytotoxic T  cells  (6). When low con- 
centrations (100 ng/ml) ofgliotoxin are used, this inhibition 
can  be  overcome by  the  addition  of IL-2.  However,  at 
higher concentrations of gliotoxin, T  cell activation is sup- 
pressed even in the presence of cytokines. In addition to 
the inhibition of lymphocyte stimulation and proliferation, 
gliotoxin also induces apoptosis in these cells as well as in 
macrophages,  L929  fibroblasts,  and  squamous  carcinoma 
cells in vitro (7-9). In vivo, gliotoxin induces apoptosis in 
thymocytes, spleen cells, and cells of the mesenteric lymph 
nodes (5). 
Gliotoxin exerts its immunosuppressive effects in part by 
inhibiting activation and proliferation of B and T  cells. We 
therefore investigated whether the toxin interferes with the 
activation of transcription factors that are crucially involved 
in B  and T  cell activation and proliferation: nuclear factor 
(NF-KB1/Ikel),  nuclear  factor  of activated  T  cells  (NF- 
AT),  and  signal  transducer  and  activator of transcription 
(STAT)  factors.  NF-KB is  a  central mediator of the  im- 
mune response (10). It regulates the transcription of various 
inflammatory  cytokines,  hematopoetic  growth  factors, 
growth factor receptors, and cell adhesion molecules (listed 
in detail in reference 10).  In most cell types, NF-KB is se- 
questered in an inactive, cytoplasmic complex by binding 
to IKB, its inhibitory subunit (11). A large variety ofT or B 
cell-activating stimuli  rapidly induce  NF-KB,  stimulating 
~B-dependent transcription. Many NF-KB target genes en- 
code proteins controlling cell proliferation. NF-mB activa- 
tion requires phosphorylation and proteolytic degradation 
of IKB  subunits  (12-16).  The  active  NF-KB  complex, 
which translocates to the nucleus, is frequently composed 
of a  heterodimer of p50  and  P,  elA  (p65)  subunits  (17). 
Whereas mouse null mutants  of p50  are viable and show 
only a  very weak immunodeficient phenotype  (18),  null 
mutants of R.elA die in utero and show massive apoptosis 
in the liver (19).  Mice lacking c-tel are defective in lym- 
phocyte proliferation, humoral immunity, and IL-2 expres- 
sion  (20).  Pharmacological inhibition  of NF-Jd3  in  vivo 
may thus affect immune regulation as well as cell survival. 
The NF-AT family of transcription factors, whose mem- 
bers share weak sequence similarity with NF-mB/Rel pro- 
teins,  also  plays  an  important  role  in  T  cell  activation. 
These  proteins  regulate  the  expression  of the  genes  for 
IL-2, -3,-4, GM-CSF, and TNF-ot (21). Activation of cy- 
toplasmic  NF-AT  factors requires  the  calcium-  and  cal- 
modulin-dependent phosphatase calcineurin, nuclear trans- 
location of NF-AT, and the association of NF-AT with an 
AP-1  factor on the DNA  (for reviews see  references 22, 
23). The importance of NF-AT in T  cell activation is illus- 
1Abbreviations used in  this paper: CR.EB, cyclic AMP response element 
binding protein; DTT, dithiothreitol; EMSA, electrophoretic  mobility 
shift assay; ICAM-1, intercellular  adhesion molecule 1; IlkF, interferon 
regulatory factor;  ISGF3, IFN-stimulated  gene factor  3; ISRE, IFN-stim- 
ulated response  element;  LIF,  leukemia inhibitory  factor;  NF-AT, nuclear 
factor of  activated  T cells; NF-Y,B, nuclear  factor  KB; STAT, signal trans- 
ducer and activator  of transcription. 
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trated by the effect of the fungal metabolites cyclosporin A 
and  FK506.  These  agents  indirectly  inhibit  calcineurin 
thereby preventing NF-AT activation (24,  25). Treatment 
of patients with cyclosporin A  or FK506  causes  a potent 
immunosuppression  that  is  exploited  clinically for  organ 
transplantation (26--28).  Natural immunosuppressive com- 
pounds with specificity for NF-mB have not yet been re- 
ported. 
Stimulation of cells in response to IFNs is mediated by 
the STAT family of transcription factors. Like NF-AT and 
NF-mB/R.el proteins, STATs are maintained in a cytoplas- 
mic form in unstimulated cells (29). STAT activation occurs 
via direct phosphorylation by receptor-associated tyrosine 
kinases,  subsequent dimerization via SH2 domains, and nu- 
clear  translocation  (30).  Stimulation  of cells  with  type  I 
IFN  (IFN-Ix/13)  causes  activation of STAT1 and STAT2, 
which  subsequently  form  a  transcription  factor,  ISGF3, 
which consists ofa STAT1-STAT2 heterodimer in associa- 
tion with a 48-kD DNA-binding protein. This 48-kD sub- 
unit belongs to the IR.F family of  proteins (30). ISGF3 acti- 
vates  transcription  of target  genes  like  MHC  class  I  by 
associating with a promoter DNA sequence designated the 
interferon-stimulated response element (ISRE). In contrast, 
type II IFN (IFN-~/)  exclusively activates STAT1 so that a 
homodimer is formed that binds to a distinct response ele- 
ment,  the  gamma  interferon  activation  site  (GAS;  30). 
Other  cytokines and  growth  factors,  including prolactin, 
epidermal growth factor, IL-2, -3, -4, -6, -12, LIF, eryth- 
ropoietin, and growth hormone also  use members of the 
STAT factor family as signal transducers (31-36). 
We show here that nanomolar concentrations of gliotoxin 
specifically inhibited the activation of NF-KB in various cell 
types, whereas the activation of NF-AT and STAT factors 
was not affected at such low concentrations. The toxin pre- 
vented stimulation of KB-controlled reporter gene activity 
by TNF, IL-1, and PMA whereas it did not affect induc- 
tion in response to IFN-~/. NF-KB activation in response to 
five different stimuli (LPS, IL-I[~, TNF-(x, PMA/PHA, and 
okadaic acid)  was blocked, suggesting that gliotoxin inter- 
fered with a late step in a common signaling cascade lead- 
ing  to  NF-v,B  activation.  Very  high  concentrations  of 
gliotoxin inhibited  NF-KB DNA  binding  in  vitro,  most 
likely because  of oxidation  of a  cysteine residue  by  the 
toxin's sulthydryl group.  However, this  modification did 
not  occur  in  vivo:  overexpressed  p50  and  cytoplasmic 
NF-KB complexed with IKB were not inactivated by the 
toxin.  Inhibition of NF-~B  activation most likely results 
from inhibition of IKB-ot proteolysis. Our data suggest that 
the  immunosuppressive  activity of the  fungal  metabolite 
gliotoxin may rely on inhibition of the transcription factor 
NF-KB in T  and B cells. 
Materials and Methods 
Cell Culture 
Jurkat,  70Z/3,  D10.G4.1,  and  stably transfected A549  ceUs 
were maintained in 1LPMI 1640 medium; HeLa $3 and 293 ceils were maintained in DMEM. Both were supplemented with 10% 
FCS  and  50  p~g/ml  penicillin-streptomycin (all  from  GIBCO 
BILL,  Eggenstein, Germany). Medium for D10.G4.1  cells con- 
tained 50 ~g/ml [3-ME and 50 U/ml IL-2 in addition. The 70Z/3 
cells transfected with  the  p55  TNF  receptor were  generously 
given  by  Dr.  M.  Kr6nke  (Kiel,  Germany);  gliotoxin,  methyl- 
thiogliotoxin  (bis-dethio-bis(methylthio)-gliotoxin), P/VIA, and 
LPS were purchased from Sigma Chemical Co.  (Miinich, Ger- 
many). Other chemicals were obtained from the following sup- 
phers: okadaic acid (Paesel and Lorei GmbH & Co., Hanan, Ger- 
many),  IL-l[3  (Genzyme  Corp.,  Cambridge,  MA)  and  TNF 
(Boehringer-Mannheim, Mannheim, Germany). 
Transfections 
293 cells were plated 12-16 h before transfection at a density 
of 106 cells per 60-mm dish. Transfections were performed using 
calcium phosphate precipitation as previously described (16). 
Transactivation Assays 
A549 cells, stably transfected with the plasmid pGLH3 carrying 
a hiciferase reporter gene driven by a fragment of the intercellular 
adhesion molecule (ICAM) 1 promoter (bp -277 to -9  relative 
to the start of transcription) carrying response elements for both 
TNF-a  and  IFN-~/  (37-39),  were  seeded in  microtiter plates. 
Cells were pretreated with either 1 Ixg/ml gliotoxin or 3 I.tg/ml 
bis-dithio-bis(methylthio)-gliotoxin  for  30  rain  before stimula- 
tion with either 300  U/ml TNF-ot,  1 ng/ml IL-I~, 20  ng/ml 
PMA, or 300 U/ml IFN-~/ for 6 h. Cells were harvested in situ 
using a commercial lysis buffer and luciferase assay system (Pro- 
mega  Corp.,  Heidelberg,  Germany)  and luciferase activity was 
determined  on  a  microplate  scintillation counter  (TopCount; 
Packard Instruments Co., Inc., Meriden, CT). 
Plasmids 
The  expression vector containing amino acids  1-399  of the 
NF-KB p50 subunit has been previously described in detail (40). 
Electrophoretic Mobility Shift Assays 
NF-KB, Oct-l, and CREB.  Total cell extracts were prepared 
using a high salt detergent buffer (Totex buffer) (20 mM Hepes, 
pH 7.9, 350 mM NaC1, 20% (vol/vol) glycerol, 1% (wt/vol) NP- 
40,  1 mM  MgC12, 0.5  mM EDTA,  0.1  mM  EGTA,  0.5  mM 
dithiothreitol [DTT], 0.1% PMSF, and 1% aprotinin). Cells were 
harvested  by  centrifugation,  washed  once  in  ice-cold  PBS 
(Sigma)  and resuspended in four cell volumes of Totex buffer. 
The cell lysate was incubated on ice for 30 min, then centrifuged 
for 5 min at 13,000g at 4~  The protein content of the superna- 
tant was determined and equal amounts  of protein (10-20  ~,g) 
were added to a reaction mixture containing 20 btg BSA (Sigma), 
2  ~g poly (dl-dC) (Boehringer Mannheim), 2 ~1 buffer D + (20 
mM  Hepes,  pH  7.9,  20%  glycerol,  100  mM  KCI,  0.5  mM 
EDTA,  0.25%  NP-40,  2  mM  DTT,  and  0.1%  PMSF),  4  btl 
buffer F (20% Ficoll-400, 100 mM Hepes, 300 mM KC1, 10 mM 
DTT, 0.1% PMSF), and 100,000 cpm (Cerenkov Counting) of a 
32p-labeled ohgonucleotide in a final volume of 20 btl. Samples 
were incubated at room temperature for 25 rain. NF-JcB, CREB, 
and  Oct-1  ohgonucleotides  (Promega)  were  labeled  using 
~/-[32p]ATP  (3,000  Ci/mmol;  Amersham International, Braun- 
schweig, Germany) and T4 polynucleotide kinase (Promega). 
DOC Activation.  DOC activation was performed precisely as 
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previously described (11);  the detergent (purchased from Sigma) 
was added to a final concentration of 0.4%. 
NFoAT.  Nuclear  extracts were  prepared as  previously de- 
scribed (41). Electrophoretic mobility shift assay (EMSA)-binding 
reactions were identical to those used for NF-rd3, Oct-l, and CREB 
except that only 0.2 ~g/ml poly (dl-dC) was used. 
S TAT Factors 
ISGF3 activation was determined in an EMSA using the ISRE 
from the promoter of the ISG15 gene (42) as a probe. HeLa $3 
cells were treated for 12 h with 1 ng/ml IFN-~ followed by a 30- 
min  stimulation  with  1,000  U/ml  of IFN-el  before  harvest. 
Where indicated, gliotoxin was added 30 min before addition of 
IFN-e~ and remained in the culture medium during IFN stimula- 
tion. The EMSA conditions have been described previously (29). 
For in vitro treatment of ISGF3 with gliotoxin, the extracts were 
treated with the indicated concentrations of the drug for 30 min at 
room  temperature  before  addition  to  the  EMSA-binding  re- 
action. 
Immunoprecipitation and Kinase Assays 
Jurkat cells (2 ￿  10  v) were pretreated with different concentra- 
tions ofgliotoxin for 1 h and subsequently stimulated with 50 ng/ 
ml PMA for 30 min. Cells were washed with ice-cold PBS con- 
taining 400 ~M EDTA and 400 I~M sodium vanadate and lysed 
in 250  ~1 of RIPA buffer (5 mM EDTA,  150 mM NaC1,  0.1% 
SDS, 1% Triton X-100,  100  ~,M Na3VO4,  1 mM DTT,  1 mM 
PMSF,  10 ~g/ml leupeptin, and 10 mM sodium phosphate, pH 
7.4).  Nuclei and cell debris were removed by centrifugation at 
16,000 g for 15 rain at 4~  The supematant was precleared with 
protein A-Sepharose (Pharmacia LKB, Freiburg, Germany) and 
immunoprecipitated with 1 ~g of rabbit anti-p56  ]ck or anti-p59  cy" 
antibody (Upstate Biotechnology, Inc.,  Lake Placid,  NY).  Im- 
mune  complexes were collected with protein A-Sepharose and 
washed twice with lysis buffer, once with 10 mM Hepes, pH 8.0, 
containing 50 mM NaC1,  and once with Hepes buffer without 
NaC1. Immune complex kinase assays were performed by incuba- 
tion at 25~  in 50  I~1 kinase buffer (30  mM Hepes, pH 7.2,  5 
mM MgC12, 5 mM MnC12, 1 ~M ATP, and 10 btCi ~-[32p]ATP) 
containing 5  ~g of acid-treated rabbit muscle enolase (Sigma). 
After 15 min, the reaction was ended by the addition of Laemmli 
buffer. The samples were analyzed by 10% SDS-PAGE and sub- 
jected to autoradiography. 
Western Blotting 
Total cell extracts (100  ~g)  were boiled in Laemmli sample 
buffer and subjected to  SDS-PAGE. Before  transfer,  gels were 
equilibrated in ice-cold blotting buffer (48 mM Tris, 39 mM gly- 
cine, 15% methanol, and 0.037% SDS). Proteins were transferred 
at 2.5 mA/cm  2 for 1 h onto Immobilon P membranes (Millipore 
Corp., Eschborn,  Germany) using a semi-dry blotting apparatus 
(Bio-Rad Laboratories, Miinich,  Germany).  Transfer  efficiency 
was monitored by Ponceau S staining of membranes. Nonspecific 
binding sites were blocked by immersing the membrane in TBST 
blocking solution  (10  mM  Tris-HC1,  pH  8.0,  150  mM  NaC1, 
0.1%  Tween  20  [vol/vol])  containing  5%  low-fat  dried  milk 
powder) overnight at 4~  After a short wash in TBST, the mem- 
branes were incubated in a 1:700  dilution of anti-Ivd3-oe antibody 
(12) in blocking solution for 1 h  at room temperature, followed 
by extensive washing with TBST. Bound antibody was decorated 
with  goat  anti-rabbit/horseradish  peroxidase  conjugate  (Bio- Rad;  diluted  1:3,000  in blocking solution)  for 30  rain at room 
temperature.  After  washing for  45  nain,  the  immunocomplexes 
were detected using enhanced chemiluminescence Western blot- 
ting  reagents  (ECL;  Amersham).  Exposure  to  Eastman  Kodak 
XAR-5 film (Rochester, NY) was performed for 30 s. 
Results 
Gliotoxin Is a Potent Inhibitor  of NF-~B Activation.  To  in- 
vestigate whether  gliotoxin interferes with the activation of 
transcription factors involved in T  cell activation, Jurkat T 
cells were incubated with various concentrations ofgliotoxin 
Figure  1.  (A) The effect of gliotoxin on NF-r,B DNA 
binding. Jurkat cells were treated for 1 h with gliotoxin at 
the concentrations indicated and were subsequently stimu- 
lated with  50  ng/ml PMA and 5  ~g/ml PHA  for  1 h. 
(Lane  1)  Unstimulated control  cells;  (lane  3)  cells were 
treated  with  gliotoxin  alone.  Equal  amounts  of protein 
from  cell  extracts  were  analyzed  for  NF-KB  activity  by 
EMSA.  A section of a fluorogram is shown. (~1) Position 
of NF-KB  DNA  complexes.  (C)) A  nonspecific  activity 
binding to the probe;  (<]) unbound oligonucleotide.  (B) 
The effect of gliotoxin on DNA binding of transcription 
factors Oct-1 and CREB. The Jurkat cells extracts used in 
A were analyzed  for CREB and Oct-1  DNA binding by 
EMSA. A section ofa fluorogram is shown. 
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PMA/PHA,  after which  total cell extracts were prepared. 
The extracts were analyzed for NF-~B DNA-binding activ- 
ity in an EMSA. Stimulation with PMA/PHA induced one 
novel  DNA-binding  activity in Jurkat  T  cells  (Fig.  1 A, 
lane 2).  Antibody reactivity and competition assays identi- 
fied this complex as a NF-v,B p50/p65 heterodimer (data not 
shown;  15,  43). NF-KB activation was significantly reduced 
by  treatment  of Jurkat  cells  with  70  ng/ml  of gliotoxin, 
whereas 100 ng/ml (300 nM) gliotoxin and higher concen- 
trations completely prevented NF-v,B induction  (Fig.  1 A, 
lanes  7 and  8).  The weak basal activity of NF-KB  (lane  1) 
was not reduced even at very high gliotoxin concentrations 
(lanes  10-14), indicating that the toxin did not directly in- 
hibit NF-KB DNA binding.  A  very similar dose-response 
was observed in the HeLa tumor cell line as well as in vari- 
ous  other  cell lines  (see  below;  data not  shown).  A  faster 
migrating,  nonspecific  DNA-binding  activity was  not  al- 
tered by gliotoxin treatment, even when doses <~50 ~g/ml 
were used (Fig.  1 A, lane  14). 
We analyzed the Jurkat T  cell extracts shown in Fig. 1 A 
in EMSAs using DNA probes containing consensus motifs 
for the  constitutively bound  transcription factors Oct and 
CREB (Fig.  1 B). Treatment with gliotoxin concentrations 
450  ~g/ml  did  not  detectably  affect  DNA  binding  of 
Oct and  CREB proteins  to  their  respective DNA probes. 
Taken  together,  these  data  show  that  treatment  of cells 
with gliotoxin at nanomolar concentrations specifically in- 
hibits the activation of transcription factor NF-v,_B, whereas 
the DNA-binding activity of other transcription factors re- 
mained unaffected at up to 500-fold higher concentrations. 
Gliotoxin Is an Inhibitor of NF-KB-dependent  Gene Expres- 
sion.  The  inducible  expression  of the  ICAM-1  gene  in 
response  to  TNF-cx,  IL-113,  and  PMA is  controlled  by a 
NF-v,B-binding site in its upstream promoter, whereas the 
inducibility in response to IFN-~/is controlled by a binding 
motif for STAT1  (37-39).  Here,  we  tested  the  effect of 
gliotoxin on the expression of a stably integrated firefly lu- 
ciferase reporter gene under  control  of a  fragment of the 
human ICAM-1 promoter in A549 cells  (37).  As shown in 
Fig. 2, TNF-o~, IL-I[~, PMA, and IFN-~/caused a substan- 
tial  induction  of the  reporter  gene.  1  ~g/ml  gliotoxin, 
which did not affect the basal ICAM-1 promoter activity, 
suppressed reporter gene induction by TNF-o~, IL-I[~, and 
PMA,  which  act via the  v,B motif. By contrast,  gliotoxin 
could not suppress induction of the ICAM-1 promoter by 
IFN-% which is mediated by STAT  transcription  factors. 
These data provide compelling evidence for the specificity 
of the  toxin.  The  inhibitory  activity of gliotoxin  on  KB- 
dependent  gene  expression  relied  on  intact  sulfhydryl 
groups; 3 ~g/ml of the immunologically inactive derivative 
methylthiogliotoxin (44,  45) did not display any inhibitory 
potential (Fig.  2). At higher concentrations ofgliotoxin, in- 
hibitory as well as stimulatory effects on the activity of var- 
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Figure  2.  The  effect of gliotoxin on ICAM-I 
promoter-driven reporter gene activity. A549 cells 
stably transfected with a luciferase reporter gene 
driven by a fragment of the  ICAM-1 promoter 
were  treated for  30  rain with either  1 ~g/ml 
gliotoxin or 3 ~g/ml methyl gliotoxin as indicated. 
Subsequently, cells were induced with either 300 
U/ml TNF-~, 1 ng/ml IL-113, 20 ng/ml PMA, or 
300 U/ml IFN-~/for 6 h and luciferase activity  was 
determined. The results are given in arbitrary rela- 
tive light units and are representative of three ex- 
periments. ious unrelated promoters and enhancers were  observed in 
reporter gene assays (data not shown),  suggesting that only 
low  concentrations  of gliotoxin  specifically affected  NF- 
r  Functional analysis of the ICAM-1 promoter thus cor- 
roborates data obtained from EMSAs showing that  nano- 
molar concentrations of gliotoxin potently and specifically 
inhibit NF-Kt3 activation. 
Gliotoxin Does Not Impair Activation of STA T and NF-A T 
Factors.  To further investigate the specificity ofgliotoxin, we 
studied the activation of STAT and NF-AT factors by IFNs 
and PMA/ionomycin, respectively. The effect of gliotoxin 
on  the  activation of STAT  factors was  tested in  HeLa  $3 
cells. In these  cells, NF-KB activation is also inhibited by 
pretreatment with 100 ng/ml of gliotoxin (data not shown). 
Extracts from control or IFN-(x/~/--stimulated cells were as- 
sayed in an EMSA using an ISRE as the DNA probe (Fig. 
3  A).  Pretreatment of HeLa  $3  cells with IFN-~/ for  12  h 
increases the amount  of the  48-kD  DNA-binding subunit 
of ISGF3 (1048) and therefore the amount of ISGF3 gener- 
ated after a  subsequent pulse with IFN-et (46).  Moreover, 
under these conditions, elevated amounts of ISGF2/I1KF1, 
another  ISKE-binding factor,  are  observed.  Since  induc- 
tion of the ISGF2/IRF1 gene by IFN depends on STAT1 
binding  to  a  GAS  sequence  in  the  IRF1  promoter  (47), 
these conditions also determine whether STAT1 homodimer 
activation is intact. Doses of ~<10  i~g/ml gliotoxin did not 
significantly  perturb  the  activation  of  STAT1,  STAT2, 
IRF-2,  and  p48  in  response  to  IFN-tx/~  stimulation  of 
HeLa $3 cells (Fig. 3 A, lanes 4-7). Similarly, treatment of 
extracts  from  IFN-ot/~/-stimulated  HeLa  $3  cells  with 
gliotoxin under  cell-flee conditions  had  no  effect  on  the 
DNA-binding of these factors (Fig. 3  B). 
D 10.G4.1  T  cells behaved similarly to Jurkat T  cells with 
respect to the inhibition of NF-KB activation by gliotoxin 
(data not  shown).  In nuclear extracts of these  cells, treat- 
ment  with  PMA/ionomycin  strongly induced  an  activity 
that binds to the distal NF-AT site in the murine IL-2 en- 
hancer (Fig. 4, compare lanes  1 and 2). This protein-DNA 
complex is specifically competed by an excess of unlabeled 
oligonucleotide (data not shown).  T  cells were treated for 
1 h  with increasing concentrations of gliotoxin followed by 
a  1-h  stimulation  with  PMA/ionomycin.  Activation  of 
NF-AT  from  its  cytoplasmic form  was  not  affected  by  a 
treatment  of D10.G4.1  T  cells with  gliotoxin,  even  at  a 
concentration  of  10  Ixg/ml,  100-fold  the  concentration 
that abbrogated activation of NF-KB  (see Fig.  1).  As seen 
Figure 3.  The effect ofgliotoxin on DNA binding of STAT factors in vitro and in vivo. (A) HeLa S3 cells  were treated in vivo for 12 h with IFN-~/ 
and subsequently with IFN-ee for 30 min. The indicated concentrations of gliotoxin were added 30 min before addition of IFN-el and remained in the 
culture medium during IFN stimulation. Equal amounts of protein from whole cell extracts were analyzed for STAT factor binding by EMSA. (Lane 7) 
A 100-fold excess of unlabeled ohgonucleotide was added as a competitor. A section of a fluorogram is shown. ('ql) Positions of various STAT factor 
DNA complexes. (/3) Unstimulated HeLa $3 cells (lane 1) or cells stimulated with IFN-'y and IFN-et as described for A (lanes 2-7) were used to prepare 
whole cell extracts. The extracts were treated with various concentrations of gliotoxin in vitro as indicated. Equal amounts of protein from cell extracts 
were analyzed  for STAT factor binding by EMSA. (Lane 3) A 100-fold excess of unlabeled ohgonucleotide was added as a competitor. A section of a flu- 
orogram is shown. (4) Positions of various STAT factor DNA complexes. 
1834  Gliotoxin Inhibits NF-KB Figure 4.  The effect  ofgliotoxin on NF-AT DNA binding. D10.G4.1 
cells were treated for 1 h with gliotoxin at the concentrations  indicated 
and were subsequently  stimulated with 50 ng/ml PMA and 1 p,M iono- 
mycin for 1 h.  (Lane 1) Unstimulated control cells were used. Equal 
amounts of  protein from nuclear extracts  were analyzed  for NF-AT activ- 
ity by EMSA. (41) Position of NF-AT DNA complexes. (<3) Unbound 
oligonucleotide. 
in previous experiments (Figs.  1-3), none of the unrelated 
nonspecific DNA-binding  activities was  sensitive towards 
gliotoxin. Taken together, these data show that treatment 
of cells with  gliotoxin specifically inhibits  the  activation 
of transcription  factor NF-gB  whereas  other constitutive 
and inducible factors remain unaffected at up  to  500-fold 
higher concentrations. In the following, we examined sev- 
eral steps in the signal transduction pathway, which lead to 
NF-r,B activation in B  and T  cells, for their susceptibility 
to gliotoxin. 
Gliotoxin  Acts on a Common  Mechanism of NF-KB Activa- 
tion.  NF-r,B  can be activated by numerous stimuh  (10). 
Reporter gene assays using the ICAM-1  promoter (Fig.  2) 
showed  that  gliotoxin  inhibits  NF-r,B  activation  in  re- 
sponse to several different stimuli, suggesting that the toxin 
targets a signal  transduction step shared by many inducers. 
To test this hypotesis, we used the pre-B cell line 70Z/3, in 
which NF-r,B can be activated by such diverse stimuh  as 
PMA, LPS, IL-1~3, or the phosphatase 2A inhibitor okadaic 
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acid. In a stably transfected 70Z/3  clone carrying the p55 
TNF  receptor  (48),  NF-r,B  can  also  be  induced  with 
TNF-et.  70Z/3  or  70Z/3-p55  cells  were  preincubated 
with 1 p,g/ml of gliotoxin for 1 h before stimulation with 
the various NF-r,B inducers. The stimuli induced NF-gB 
DNA-binding activity to different levels (Fig.  5). Pretreat- 
merit with gliotoxin completely prevented the activation of 
NF-r,B by all five stimuli, indicating that the toxin inter- 
fered with a common event shared by all inducers. 
Only  Very High  Concentrations of Gliotoxin  Inactivate NF- 
KB DNA Binding.  A simple explanation for the inhibitory 
effect of gliotoxin would be a direct interference with the 
DNA-binding assay detecting NF-,<B.  Gliotoxin is a sulf- 
hydryl compound with the potential to covalently modify 
proteins by formation of mixed disulfides with exposed cys- 
teine residues (3). NF-r,B subunits harbor a redox-sensitive 
cysteine residue  in  their DNA-binding  domains  (49-51). 
In  addition,  gliotoxin  has  been  shown  to  cause  DNA 
breaks at 90 p,g/ml in vitro (52),  such that high gliotoxin 
concentrations  may  impair  DNA-binding  reactions  by 
damaging the oligonucleotide probe. To test these possibil- 
ities,  we incubated cell extracts from PMA/PHA-activated 
Jurkat T  cells  containing activated NF-gB with gliotoxin. 
Addition of 25 p,g/ml gliotoxin to the DNA-binding reac- 
tion  did  not  detectably inhibit  NF-gB  DNA  binding  in 
vitro  (Fig.  6,  lane  3).  Only  concentrations  I>250  p,g/ml 
impaired DNA binding of NF-gB (Fig. 6, lanes 4 and 5). 
It is  possible  that  in  intact  cells  gliotoxin is  converted 
into a metabolite that directly modifies NF-KB. We inves- 
tigated this hypothesis by transfecting 293 cells with an ex- 
pression vector for the p50 DNA-binding subunit of NF-gB. 
p50 was previously shown to be highly susceptible to mod- 
ification of Cys62 by oxidants (49, 51). Overexpressed p50 
is not subject to significant IgB inactivation and will there- 
fore constitutively bind DNA as a homodimer (53). Trans- 
fected 293 cells expressing p50 NF-,<B were treated with in- 
creasing concentrations of gliotoxin for 2 h after which cell 
extracts were analyzed by EMSA.  Concentrations of 450 
p,g/ml gliotoxin, 500-fold the inhibitory dose for NF-gB 
activation, did not impair the p50 DNA-binding activity in 
vivo (Fig.  7).  In addition, we found that the NF-r,B/I,<B 
complex in nonstimulated 70Z/3 pre-B cells, was not inac- 
tivated by gliotoxin treatment; deoxycholate treatment (11) 
recovered similar  amounts  of NF-r,B  activity in  cell  ex- 
tracts from control and gliotoxin-treated cells (Fig. 8, com- 
pare lanes 2 and 4). Taken together, these data suggest that 
gliotoxin does not directly modify NF-KB DNA-binding 
subunits in vivo. 
Gliotoxin  Does Not  Prevent Activation  of Tyrosine Kinases 
p56  ~k or p59~" upon T  Cell Activation.  An early event after 
stimulation of the TCR is the activation of the Src-hke ty- 
rosine kinases p56  lck and p59@" (54, 55). Extracts from con- 
trol and gliotoxin-treated Jurkat T  cells were used for im- 
munoprecipitation with antibodies against  p56  lck or p59  fy". 
Kinase activities were determined by incubation of immu- 
noprecipitates with the substrate rabbit muscle enolase and 
~-[32p]ATP.  Tyrosine-phosphorylated  enolase  was  then 
separated by SDS-PAGE and visualized by autoradiography Figure 5.  The effect of gliotoxin on NF-KB 
activation  in  response  to  five  distinct  stimuli. 
70Z/3 pre-B cells were stimulated with 50 ng/ 
ml PMA (lanes 2  and  9),  50 U/ml of IL-1-[3 
(lanes 3 and  10), or 10 vtg/ml of LPS (lanes 4 
and  1  I). A stably transfected 70Z/3 clone,  ex- 
pressing the p55 TNF receptor,  was stimulated 
with 200 U/ml of TNF (lanes 6 and  13) or 0.5 
laM okadaic acid (lanes 8 and  14). In lanes 1, 5, 
8, and  12 the appropriate  unstimulated  control 
cells were used. The cells analyzed in lanes 8-14 
were pretreated  with 1 lag/ml gliotoxin for 1 h 
before  stimulation.  Equal  amounts  of protein 
from cell extracts were analyzed for NF-KB ac- 
tivity  by EMSA.  A  section  of a fluorogram  is 
shown.  ('q)  Position  of NF-KB  DNA  com- 
plexes. (O) A nonspecific activity binding to the 
probe;  (<3) unbound oligonucleotide. 
(Fig.  9).  Stimulation  of Jurkat  cells with  PMA  resulted  in 
8.8-  and  6.7-fold  induction  of enolase  phoshorylation  by 
p56 lck and p59 ~yn immunoprecipitates,  respectively (data not 
shown).  Treatment ofJurkat T  cells with gliotoxin concen- 
trations  ~<10  wg/ml did not detectably affect the ability of 
either p56 lck or p59 fyr' to phosphorylate  rabbit  muscle  eno- 
lase  (Fig. 9),  suggesting that  gliotoxin did not prevent NF- 
KB  activation  by  inhibiting  TC1K-associated  tyrosine  ki- 
nases. 
Gliotoxin  Allows  IKB-oe  Phosphorylation  but  Prevents  Its 
Degradation.  Release oflKB-oe from NF-KB requires phos- 
phorylation  of IKB-ci on serines 32  and  36 and subsequent 
proteolytic  degradation  of IKB-cx by the ubiquitin/protea- 
some  pathway  (12-16).  The  inducible  phosphorylation  of 
Figure  6.  The  effect  of  in 
vitro  addition  of  gliotoxin  on 
NF-KB  DNA binding.  Extracts 
from PMA/PHA-stimulated Jur- 
kat cells were analyzed for NF-r,B 
DNA  binding  by  EMSA.  The 
indicated  amounts  of gliotoxin 
were added  to the EMSA-bind- 
ing reactions in vitro. 
Figure 7.  The effect ofgliotoxin on p50 DNA binding.  293 cells were 
transiently transfected with 6  lag of a p50  expression vector.  24 h  after 
transfection, cells were treated with various concentrations  ofgliotoxin, as 
indicated,  for 2  h.  Total  cell  extracts  were  prepared  and  analyzed  by 
EMSA using a 3zp-labeled oligonucleotide  probe containing  a NF-KB- 
binding site. A section  of a fluorogram  is shown.  ('q)  The NF-KB p50 
homodimer DNA complex.  (<1) Unbound oligonucleotide. 
1836  Gliotoxin Inhibits NF-KB Figure 8.  Activation of NF-gB DNA binding by DOC sodium deoxy- 
cholate treatment. 70Z/3 pre-B cells were treated with 1 ~g/ml gliotoxin 
(lanes 3 and 4) or left untreated (lanes 1 and 2). In lanes 2 and 4 the deter- 
gent DOC was added to cell extracts for 15 n-fin to a final concentration 
of 0.4%. Subsequently, the cell extracts were analyzed  for NF-r.B activity 
by EMSA. A section of a fluorogram is shown. (~1) Position of NF-r,B 
DNA complexes. ((3) A nonspecific activity binding to the probe. 
Ir,  B  is readily detected in Western blots as a slight decrease 
in  protein  mobility.  Jurkat  T  ceils  were  treated  with 
gliotoxin for 1 h  and stimulated with 0.5  btM okadaic acid 
for 60  min.  IKB-oe was detected on Western blots using a 
polyclonal antibody (12). In control cells, okadaic acid stim- 
ulation led to both a decreased mobility of IKB-Ix and a re- 
duction in  the  total amount  of ImB  (Fig.  10,  top,  lane  2), 
which coincided with NF-KB activation in EMSAs (bottom, 
lane  2).  In  gliotoxin-treated cells,  the  inducible  mobility 
decrease  of IgB-ot in  response  to  okadaic  acid is still ob- 
served  (Fig.  10,  top,  lane  4),  indicating that  the  toxin did 
not inhibit the IKB-o~ kinase. However,  more phosphory- 
lated IKB-ci was present and, consequently, less NF-mB ac- 
tivated (Fig.  10,  bottom,  lane  4)  than under control condi- 
tions  (compare  lanes  2  and  4),  suggesting  that  gliotoxin 
interfered with IKB-ot degradation. 
Discussion 
Invasive aspergillosis represents one  of the most diflficult 
therapeutic problems in immunocompromised patients. De- 
Figure 10.  The effect ofgliotoxin on Iv.B-ct  phosphorylation and pro- 
teolytic degradation. Jurkat T cells were treated with I  ~g/ml gliotoxin 
for 1 h before stimulation with 0.5 I~M okadaic acid for 60 rain.  (Top) 
Cell extracts were analyzed by SDS-PAGE and Western blotting with an 
anti-IgB-c~ polydonal  antibody.  (Bottom) Extracts were  analysed for 
NF-KB activity by EMSA. A section ofa fluorogram is shown. (~1) Posi- 
tion of NF-KB DNA complexes and nonspecific binding to the DNA 
probe (n.s.) 
spite  therapy  with  the  antifungal  agent  Amphotericin  B, 
mortality rates range between 75 and 100% (56). This chal- 
lenge is compounded by the lack of knowledge about the 
molecular  mechanism  of Aspergillus  pathology.  The  sec- 
ondary fungal metabolite gliotoxin, synthesized by A. fumi- 
gatus and other pathogenic fungi, can be isolated from peri- 
toneal  lavages  of mice  undergoing  systemic  experimental 
aspergillosis (3).  To  date, however,  gliotoxin has not been 
implicated directly in  the pathogenesis of aspergillosis and 
its mechanism of action remains a matter of debate (57, 58). 
We  show  here  that  gliotoxin inhibits  the  activation  of 
transcription factor NF-r,B,  a  central mediator of the  hu- 
man immune reponse. NF-KB activates the transcription of 
various cytokine genes including those for IL-1, IL-2, GM- 
CSF,  G-CSF,  M-CSF,  and  IL-6  (10).  Gliotoxin  inhibits 
Figure 9.  The effect of gliotoxin on the activity 
of p56  kk and p59  fyn. Jurkat cells were treated with 
various concentrations of gliotoxin as indicated for 
1 h before stimulation with 50 ng/ml PMA for 10 
min.  CeU extracts were  imrnunoprecipitated with 
antibodies against the kinases  p56  l& and p59  ~yn. Pre- 
cipitated proteins were incubated with rabbit mus- 
cle enolase and ~/-[32p]ATP  for 15 min after which 
the  reaction  products  were  analyzed by  SDS- 
PAGE. 
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activated  T  cells  (6,  59).  These  effects  can  now  be  ex- 
plained  by the  inhibition  of NF-KI3 activation.  Similarly, 
gliotoxin treatment of stimulator cells prevents the induc- 
tion of alloreactive cytotoxic T  cells  in MLCs.  This most 
hkely results  from the  loss  of NF-KB-mediated IL-2 ex- 
pression (60),  since the inhibition can be overcome by the 
exogenous addition oflL-2. Gliotoxin's inhibition ofmito- 
gen-activated T  and B  cell proliferation (45) may also be a 
consequence  of NF-~I3 inhibition:  NF-KB  is  induced  by 
many B  and  T  cell mitogens such  as  LPS,  Con  A,  anti- 
CD28,  anti-CD3,  anti-IgM,  and  lymphotrophic  viruses 
(10).  By inhibiting NF-~O3 activation, gliotoxin may inter- 
rupt  one signal transduction  pathway leading to  T  and B 
cell  proliferation.  The  selective  delay  in  the  recovery of 
LPS-reponsive B  cells in gliotoxin-treated mice (5)  can be 
explained in the same manner. 
The mechanism of action by which  gliotoxin exerts its 
effect remains a matter of debate.  It has been shown that 
gliotoxin causes DNA fragmentation in vitro and in vivo. 
In vivo,  treatment  of L929  fibroblasts,  a  sheep  squamous 
cell carcinoma hne,  macrophages, or spleen  cells  with  30 
ng-1  I~g/ml of gliotoxin for 1 h  causes DNA fragmenta- 
tion (9).  Other cell types, for example the monkey kidney 
cell line Vero,  the rat mammary carcinoma MAT,  or the 
mouse  mastocytoma  cell  hne  P815  are  resistant  to 
gliotoxin-induced DNA damage. In vitro, gliotoxin shows 
no effect on DNA on its own; high concentrations of the 
toxin (0.3 mM or 90 p,g/ml) need to be incubated with re- 
ductants such as DTT or glutathione in order to produce 
DNA damage (52). 
Eichner  et  al.  (52)  proposed  that  the  DNA  damage is 
caused by the production ofH20  2 through redox-cycling of 
gliotoxin.  In this  model,  gliotoxin undergoes intracellular 
processing to the dithiol derivative, generating a redox cy- 
cle that produces superoxide anions and ultimately, H20  2. 
This  hypothesis  has  been  contradicted  by Schweizer  and 
Richter  (57),  who  find  no  evidence  for  either  redox- 
cycling or H20  2 production by gliotoxin in isolated mito- 
chondria.  Rather,  they propose that gliotoxin reacts with 
thiol groups to cause a transient release of Ca  2+ from mito- 
chondria.  Contrary to this report, Beaver and Waring (58) 
found  no  increase  in  intracellular  Ca  2+  levels when  thy- 
mocytes were treated with concentrations of gliotoxin be- 
tween  50  nM  and  10  ~M.  Only  doses  >500  mM  pro- 
duced large increases in intracellular Ca  2+ levels. 
Based on the data presented in this paper, we propose a 
new model for the mechanism of action of ghotoxin.  We 
suggest that gliotoxin's effects on immune cells are mainly 
due to the inhibition of NF-~13 activation. An inability to 
activate NF-KB is also achieved in transgenic mice, which 
carry a deletion in the gene for the p65 subunit of NF-KB. 
These animals die in utero and show severe apoptosis in the 
liver (19).  It is interesting  to  note  that  mice treated with 
gliotoxin show extensive apoptosis in spleen cells by light 
and electron microscopy and by DNA fragmentation anal- 
ysis  (5).  Both  the  fetal hver and  the  adult  spleen  are he- 
matopoietic organs. Perhaps certain hematopoietic cells re- 
quire  the  abihty  to  activate  NF-KB  in  order  to  avoid 
programmed  cell  death.  Spleens  from  gliotoxin-treated 
mice are selectively depleted of B  cells  (5).  FACS  |  analysis 
performed 16 d after gliotoxin treatment identified 37% of 
the splenocytes as B  cells whereas in control animals, 70% 
of the population were stained with a B cell marker. It ap- 
pears that the inability to activate NF-KB leads to apoptosis 
in B cells. 
We propose the following model for the mechanism of 
action of the fungal metabolite gliotoxin. By inhibiting ac- 
tivation of the transcription factor NF-KB, gliotoxin abro- 
gates B  and T  cell  stimulation,  causing a severe immuno- 
suppression.  Furthermore,  the inability to activate NF-KI3 
may cause apoptosis of B cells, compounding the immuno- 
suppressive effect. Our data suggest a direct role for gliotoxin 
in the pathology of Aspergillosis. 
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